FibroBiologics, Inc. (FBLG)

NASDAQ: FBLG · Real-Time Price · USD
0.7970
-0.0117 (-1.45%)
At close: Jun 16, 2025, 4:00 PM
0.8300
+0.0330 (4.14%)
After-hours: Jun 16, 2025, 6:32 PM EDT
-1.45%
Market Cap 30.50M
Revenue (ttm) n/a
Net Income (ttm) -7.67M
Shares Out 38.26M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 258,823
Open 0.8598
Previous Close 0.8087
Day's Range 0.7700 - 0.8598
52-Week Range 0.7013 - 7.5700
Beta n/a
Analysts Strong Buy
Price Target 13.00 (+1,531.12%)
Earnings Date Aug 6, 2025

About FBLG

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2024
Employees 13
Stock Exchange NASDAQ
Ticker Symbol FBLG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for FBLG stock is "Strong Buy." The 12-month stock price forecast is $13.0, which is an increase of 1,531.12% from the latest price.

Price Target
$13.0
(1,531.12% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the devel...

9 hours ago - GlobeNewsWire

FibroBiologics to Present at the BIO International Convention 2025

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the devel...

16 hours ago - GlobeNewsWire

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth Seasoned finance executive brings over 20 years of public company and ...

7 days ago - GlobeNewsWire

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the develo...

4 weeks ago - GlobeNewsWire

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third...

4 weeks ago - GlobeNewsWire

FibroBiologics Presenting at the ThymUS 2025 Meeting

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the deve...

6 weeks ago - GlobeNewsWire

FibroBiologics Presents at the ThymUS 2025 Meeting

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the deve...

6 weeks ago - GlobeNewsWire

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of t...

2 months ago - GlobeNewsWire

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology Located in Houston, Texas, the new facility allow...

2 months ago - GlobeNewsWire

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of t...

2 months ago - GlobeNewsWire

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing

2 months ago - GlobeNewsWire

FibroBiologics Announces 2025 Annual Meeting of Stockholders

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the deve...

2 months ago - GlobeNewsWire

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the deve...

3 months ago - GlobeNewsWire

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation.

3 months ago - GlobeNewsWire

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers Master cell bank to be used in manufacturing of CYWC628 drug product to...

3 months ago - GlobeNewsWire

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...

4 months ago - GlobeNewsWire

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing

HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...

6 months ago - GlobeNewsWire

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...

6 months ago - GlobeNewsWire

FibroBiologics Announces $25 Million Financing

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...

6 months ago - GlobeNewsWire

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeu...

7 months ago - GlobeNewsWire

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...

7 months ago - GlobeNewsWire

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the secon...

7 months ago - GlobeNewsWire

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the deve...

8 months ago - GlobeNewsWire

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel...

8 months ago - GlobeNewsWire

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development, testi...

8 months ago - GlobeNewsWire